Details for Patent: 9,061,029

Which drugs does patent 9,061,029 protect, and when does it expire?

Patent 9,061,029 protects TASIGNA and is included in one NDA.

Protection for TASIGNA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-two patent family members in thirty-seven countries.

Summary for Patent: 9,061,029

Title:	Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity
Abstract:	The present invention relates to a regimen for the administration of a pyrimidylaminobenzamide of formula I ##STR00001## wherein the radicals as defined herein, or of a pharmaceutically acceptable salt thereof, for the treatment of proliferative disorders, particularly solid and liquid tumors, and other pathological conditions mediated by the Bcr-Abl oncoprotein, the cell transmembrane tyrosine kinase receptor c-Kit, DDR1 (discoidin domain receptor 1), DDR2 (discoidin domain receptor 2) or PDGF-R (platelet derived growth factor receptor) kinase activity, wherein the pyrimidylaminobenzamide of formula I and, optionally, pharmaceutically acceptable carriers, are dispersed in a fruit preparation.
Inventor(s):	Gallagher; Neil (Basel, CH), Yin; Ophelia (Denville, NJ)
Assignee:	Novartis AG (Basel, CH)
Application Number:	13/509,626
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,061,029
Patent Claim Types: see list of patent claims	Use; Composition; Compound;

Drugs Protected by US Patent 9,061,029

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Novartis	TASIGNA	nilotinib hydrochloride	CAPSULE;ORAL	022068-003	Mar 22, 2018	AB	RX	Yes	No					Y
Novartis	TASIGNA	nilotinib hydrochloride	CAPSULE;ORAL	022068-002	Jun 17, 2010	AB	RX	Yes	No					Y
Novartis	TASIGNA	nilotinib hydrochloride	CAPSULE;ORAL	022068-001	Oct 29, 2007	AB	RX	Yes	Yes					Y

Foreign Priority and PCT Information for Patent: 9,061,029

PCT Information
PCT Filed	November 17, 2010	PCT Application Number:	PCT/US2010/056926
PCT Publication Date:	May 26, 2011	PCT Publication Number:	WO2011/062927

International Family Members for US Patent 9,061,029

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	079029
Australia	2010322102
Brazil	112012011693
Canada	2779490
Chile	2012001270
China	102612368